Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Gastric cancer-molecular and clinical dimensions.

Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA.

Nat Rev Clin Oncol. 2013 Nov;10(11):643-55. doi: 10.1038/nrclinonc.2013.170. Epub 2013 Sep 24. Review.

2.

Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.

Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D.

Cancer Treat Rev. 2011 Dec;37(8):599-610. doi: 10.1016/j.ctrv.2011.03.007. Epub 2011 Jun 14. Review.

PMID:
21676549
3.

Proteomic and metabolic prediction of response to therapy in gastric cancer.

Aichler M, Luber B, Lordick F, Walch A.

World J Gastroenterol. 2014 Oct 14;20(38):13648-57. doi: 10.3748/wjg.v20.i38.13648. Review.

4.

Current advances in targeted therapies for metastatic gastric cancer: improving patient care.

Aguiar PN Jr, Muniz TP, Miranda RR, Tadokoro H, Forones NM, Monteiro ID, Castelo-Branco P, Janjigian YY, Mello RA.

Future Oncol. 2016 Mar;12(6):839-54. doi: 10.2217/fon.15.348. Epub 2016 Feb 3. Review.

PMID:
26838766
5.

Targeted therapy in advanced gastric carcinoma: the future is beginning.

Schinzari G, Cassano A, Orlandi A, Basso M, Barone C.

Curr Med Chem. 2014;21(8):1026-38. Review.

PMID:
24304282
6.

Targeted therapies for gastric cancer: current status.

Yoong J, Michael M, Leong T.

Drugs. 2011 Jul 30;71(11):1367-84. doi: 10.2165/11592530-000000000-00000. Review.

PMID:
21812503
7.

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.

Aprile G, Giampieri R, Bonotto M, Bittoni A, Ongaro E, Cardellino GG, Graziano F, Giuliani F, Fasola G, Cascinu S, Scartozzi M.

Expert Opin Investig Drugs. 2014 Jul;23(7):925-42. doi: 10.1517/13543784.2014.912631. Epub 2014 May 7. Review.

PMID:
24806575
8.

Targeted therapy for gastric cancer--current status.

Kulig J, Kołodziejczyk P, Kulig P, Legutko J.

J Oncol Pharm Pract. 2013 Mar;19(1):75-81. doi: 10.1177/1078155212449030. Epub 2012 Jun 18. Review.

PMID:
22711713
9.

mTOR as a therapeutic target in patients with gastric cancer.

Al-Batran SE, Ducreux M, Ohtsu A.

Int J Cancer. 2012 Feb 1;130(3):491-6. doi: 10.1002/ijc.26396. Epub 2011 Oct 5. Review.

10.

Novel targeted agents for gastric cancer.

Liu L, Wu N, Li J.

J Hematol Oncol. 2012 Jun 18;5:31. doi: 10.1186/1756-8722-5-31. Review.

11.

Molecular-targeted first-line therapy for advanced gastric cancer.

Song H, Zhu J, Lu D.

Cochrane Database Syst Rev. 2016 Jul 19;7:CD011461. doi: 10.1002/14651858.CD011461.pub2. Review.

PMID:
27432490
12.

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M, Wu J, Ngo A, Manesh S, Tan E, Teh BT, So JB, Goh LK, Boussioutas A, Lim TK, Flotow H, Tan P, Rozen SG.

Gastroenterology. 2013 Sep;145(3):554-65. doi: 10.1053/j.gastro.2013.05.010. Epub 2013 May 14.

PMID:
23684942
13.

Update on metastatic gastric and esophageal cancers.

Shah MA.

J Clin Oncol. 2015 Jun 1;33(16):1760-9. doi: 10.1200/JCO.2014.60.1799. Epub 2015 Apr 27. Review.

PMID:
25918288
14.

Targeted therapy for advanced esophagogastric adenocarcinoma.

Kordes S, Cats A, Meijer SL, van Laarhoven HW.

Crit Rev Oncol Hematol. 2014 Apr;90(1):68-76. doi: 10.1016/j.critrevonc.2013.10.004. Epub 2013 Oct 12. Review.

PMID:
24183912
15.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
16.

Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.

Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH.

BMC Cancer. 2016 Mar 9;16:200. doi: 10.1186/s12885-016-2232-2.

17.

Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.

Liu Y, Chen S, Xue R, Zhao J, Di M.

Biochem Biophys Res Commun. 2016 Feb 5;470(2):350-5. doi: 10.1016/j.bbrc.2016.01.046. Epub 2016 Jan 11.

PMID:
26780727
18.

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P.

Gut. 2012 May;61(5):673-84. doi: 10.1136/gutjnl-2011-301839. Epub 2012 Feb 7.

19.

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.

Labots M, Buffart TE, Haan JC, van Grieken NC, Tijssen M, van de Velde CJ, Grabsch HI, Ylstra B, Carvalho B, Fijneman RJ, Verheul HM, Meijer GA.

Cell Oncol (Dordr). 2014 Feb;37(1):41-52. doi: 10.1007/s13402-013-0162-4. Epub 2013 Dec 31.

PMID:
24379144
20.

Incorporation of targeted agents in the management of patients with advanced gastric cancer.

Pentheroudakis G, Stoyianni A.

Curr Med Chem. 2011;18(11):1629-39. Review.

PMID:
21428884

Supplemental Content

Support Center